MIXED HEPATOCELLULAR CHOLANGIOCARCINOMA

This adverse event was reported 45 times

These drugs are most commonly taken by patients reporting MIXED HEPATOCELLULAR CHOLANGIOCARCINOMA:

# Drug Count
0 ATEZOLIZUMAB 22
1 BEVACIZUMAB 22
2 SORAFENIB 8
3 ETANERCEPT 7
4 CISPLATIN 6
5 GEMCITABINE 6
6 GEMCITABINE HYDROCHLORIDE 6
7 ADALIMUMAB 5
8 SPIRONOLACTONE 5
9 LENVATINIB 4
See all common drugs associated with MIXED HEPATOCELLULAR CHOLANGIOCARCINOMA

MIXED HEPATOCELLULAR CHOLANGIOCARCINOMA is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 PROCHLORPERAZINE EDISYLATE 1 0.0008
1 ATEZOLIZUMAB 22 0.0006
2 SORAFENIB 8 0.0004
3 CALCIUM POLYCARBOPHIL 1 0.0003
4 CEFIXIME 1 0.0003
5 REGORAFENIB 3 0.0003
6 OLAPARIB 4 0.0002
7 BEVACIZUMAB 22 0.0002
8 LENVATINIB 4 0.0001
9 MERCAPTOPURINE 2 0.0001
See all drugs enriched for association with MIXED HEPATOCELLULAR CHOLANGIOCARCINOMA